CIK 0001651308 · Large accelerated filer
BeOne Medicines Ltd.
Sign in to watch- Ticker
- BEIGF
- Exchange
- Nasdaq, OTC
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Entity type
- operating
- EIN
- 981209416
- Phone
- 41-616851900
- Business address
- C/O BEONE MEDICINES I GMBH, AESCHENGRABEN 27, 21ST FLOOR, BASEL, Switzerland, 4051
- Former names
- BeiGene, Ltd.
Securities
- ONC American Depositary Shares Nasdaq
- BEIGF Common stock OTC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $48,487,541
- in 9 filings, $47.8M under 10b5-1 plans
Net −$48,487,541. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2025-12-11 | Lee Chan Henry SVP, General Counsel | Option exercise 10b5-1 | +101 | $194.47 | $20K | 101 |
| 2025-12-11 | Lee Chan Henry SVP, General Counsel | Option exercise 10b5-1 | +133 | $213.32 | $28K | 234 |
| 2025-12-11 | Lee Chan Henry SVP, General Counsel | Option exercise 10b5-1 | +98 | $159.03 | $16K | 332 |
| 2025-12-11 | Lee Chan Henry SVP, General Counsel | Sale 10b5-1 | −332 | $325.00 | $108K | 0 |
| 2025-12-11 | Lee Chan Henry SVP, General Counsel | Option exercise · Share Option (Right to Buy) 10b5-1 | −1,313 | 33,072 | ||
| 2025-12-11 | Lee Chan Henry SVP, General Counsel | Option exercise · Share Option (Right to Buy) 10b5-1 | −1,729 | 100,477 | ||
| 2025-12-11 | Lee Chan Henry SVP, General Counsel | Option exercise · Share Option (Right to Buy) 10b5-1 | −1,274 | 120,666 | ||
| 2025-12-10 | Lee Chan Henry SVP, General Counsel | Option exercise 10b5-1 | +101 | $194.47 | $20K | 101 |
| 2025-12-10 | Lee Chan Henry SVP, General Counsel | Option exercise 10b5-1 | +133 | $213.32 | $28K | 234 |
| 2025-12-10 | Lee Chan Henry SVP, General Counsel | Option exercise 10b5-1 | +98 | $159.03 | $16K | 332 |
| 2025-12-10 | Lee Chan Henry SVP, General Counsel | Sale 10b5-1 | −332 | $318.28 | $106K | 0 |
| 2025-12-10 | Lee Chan Henry SVP, General Counsel | Option exercise · Share Option (Right to Buy) 10b5-1 | −1,313 | 34,385 | ||
| 2025-12-10 | Lee Chan Henry SVP, General Counsel | Option exercise · Share Option (Right to Buy) 10b5-1 | −1,729 | 102,206 | ||
| 2025-12-10 | Lee Chan Henry SVP, General Counsel | Option exercise · Share Option (Right to Buy) 10b5-1 | −1,274 | 121,940 | ||
| 2025-11-26 | Sanders Corazon (Corsee) D. Director | Option exercise | +2,627 | $159.03 | $418K | 2,627 |
| 2025-11-26 | Sanders Corazon (Corsee) D. Director | Sale | −1,823 | $340.20 | $620K | 804 |
| 2025-11-26 | Sanders Corazon (Corsee) D. Director | Sale | −804 | $342.47 | $275K | 0 |
| 2025-11-26 | Sanders Corazon (Corsee) D. Director | Option exercise · Share Option (Right to Buy) | −34,151 | 0 | ||
| 2025-11-17 | Wu Xiaobin President and COO | Sale | −3,155 | $380.23 | $1.2M | 836 |
| 2025-11-17 | Wu Xiaobin President and COO | Sale | −826 | $381.19 | $315K | 10 |
Page 17 of 71 · 1,406 trades